Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YUCNA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BL-M08D1
|
|||||
| Synonyms |
BL M19D1; BL-M08D1; BL-M19D1; BLM19D1
Click to Show/Hide
|
|||||
| Organization |
Sichuan Baili Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 2 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TROP2)
|
Antigen Info | ||||
| Payload Name |
Camptothecin analogue ED04
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Gly-Mal-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
brengitecan
|
|||||
